ReviewMolecular biology reports2026
From barrier to trigger: leveraging tumor hypoxia for precise control of CAR-T cell activity.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CAR-T cell therapy has revolutionized the treatment of hematologic malignancies, yet its translation to solid tumors remains a formidable challenge. A central determinant of this limitation is the hypoxic tumor microenvironment, which imposes profound immunosuppressive pressure on infiltrating CAR-T cells, impairing their persistence, effector function, and metabolic fitness. Rather than viewing hypoxia purely as an obstacle, emerging engineering paradigms are reframing it as a tumor-selective switch one that can be harnessed to spatially confine CAR-T cell activation, enhance metabolic fitness, and reduce off-tumor toxicity. This review critically examines how hypoxia subverts CAR-T cell immunity, and how next-generation hypoxia-responsive constructs, metabolic reprogramming strategies, and armored cytokine-secreting designs are beginning to turn this hostile microenvironment into a therapeutic advantage. We further discuss unresolved clinical challenges and the translational outlook for hypoxia-adapted CAR-T cells in solid tumor immunotherapy.
Indexed as
Identifiers
42455334What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.